Ultra-Sensitive Cancer Screening in 24 Hours

ExoDiscovery Detect analyzes RNA biomarkers within exosomes, achieving 10,000x greater sensitivity than conventional methods. It detects cancer signals that others miss—with 97% accuracy. For pancreatic cancer, the test detects mutations including KRAS G12C, G12D, G12R, and G12V, which account for 96% of pancreatic cancer cases.

While traditional cancer tests require weeks of waiting, ExoDiscovery Detect delivers complete results in just 24 hours . This dramatic reduction in waiting time decreases patient anxiety and enables faster clinical decision-making when time matters most.

ExoDiscovery Detect requires only a standard blood draw with minimal sample volume (20μL plasma), eliminating the need for costly, high-risk invasive procedures. Our technology seamlessly integrates with existing clinical workflows, making implementation simple for healthcare providers.